CYTK - Cytokinetics Announces Seven Upcoming Presentations at the European Society of Cardiology Congress 2024 | Benzinga
Late Breaking Clinical Trial Presentations to Feature Additional Results from SEQUOIA-HCM Related to Patient-Reported Health Status, Cardiac Structure and Function and Biomarkers
Analyses of Safety and Outcomes from FOREST-HCM Related to Withdrawal of Standard of Care Medications to be Presented
SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced seven upcoming presentations, including four Late Breaking Clinical Trial presentations related to aficamten, at the European Society of Cardiology Congress 2024, taking place in London, UK from August 30, 2024 – September 2, 2024.
Late Breaking Clinical Trials
Title: Effect of Aficamten on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy: Results from SEQUOIA-HCM
Presenter: John A. Spertus, M.D., M.P.H., Professor, Daniel J. Lauer Missouri Endowed Chair in Metabolic and Vascular Disease Research, Clinical Director, University of Missouri Kansas City Healthcare Institute for Innovations in Quality and Saint Luke's Mid America Heart Institute
Date: September 1, 2024
Topic: European Society of Cardiology
Session Title: Trial Updates and Other Studies in Hypertrophic Cardiomyopathy and Aortic Stenosis
Session Type: Late-Breaking Science
Session Time: 8:15-9:45 AM BST
Presentation Time: 8:15 AM BST
Location: Bishkek
Title: Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Presenter: Sheila Hegde, M.D., M.P.H., Cardiovascular Medicine Specialist, Division of Cardiovascular Medicine, Brigham and Women's Hospital
Date: September 1, 2024
Topic: European Society of Cardiology
Session Title: Trial Updates and Other Studies in Hypertrophic Cardiomyopathy and Aortic Stenosis
Session Type: Late-Breaking Science
Session Time: 8:15-9:45 AM BST
Presentation Time: 8:26 AM BST
Location: Bishkek
Title: Effect of Aficamten on Structure and Function in Patients with Obstructive Hypertrophic Cardiomyopathy: The SEQUOIA-HCM CMR Substudy
Presenter: Ahmad Masri, M.D., MS, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University
Date: September 1, 2024
Topic: European Society of Cardiology
Session Title: Trial Updates and Other Studies in Hypertrophic Cardiomyopathy and Aortic Stenosis
Session Type: Late-Breaking Science
Session Time: 8:15-9:45 AM BST
Presentation Time: 8:37 AM BST
Location: Bishkek
Title: Safety and Outcomes of Standard of Care Medications Withdrawal in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Aficamten in FOREST-HCM Trial